Compare XLO & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XLO | BAFN |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 40.6M |
| IPO Year | 2021 | N/A |
| Metric | XLO | BAFN |
|---|---|---|
| Price | $0.64 | $6.75 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 333.3K | 12.7K |
| Earning Date | 03-10-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,804,000.00 | ★ $58,931,000.00 |
| Revenue This Year | $626.78 | N/A |
| Revenue Next Year | $79.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | N/A |
| 52 Week Low | $0.59 | $5.72 |
| 52 Week High | $1.70 | $19.75 |
| Indicator | XLO | BAFN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 41.78 |
| Support Level | $0.63 | $5.72 |
| Resistance Level | $0.63 | $8.06 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 32.53 | 46.23 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.